JAHA:BMI与房颤的发生风险呈正相关

2018-04-20 MedSci MedSci原创

房颤的发病率逐年增加,体重指数(BMI)是房颤的危险因素,然而,性别在BMI对房颤影响中的作用尚不清楚。本研究纳入了Troms?第四次临床研究中的24799名研究对象(平均年龄为45.5±14.2岁,女性占52.9%),经过平均15.7±5.5年时间的随访,有811名(6.2%)女性和918名(7.9%)男性发展为房颤,在男性中,低的BMI可以降低房颤的发生风险,而高BMI会增加房颤的风险(HR:

房颤的发病率逐年增加,体重指数(BMI)是房颤的危险因素,然而,性别在BMI对房颤影响中的作用尚不清楚。本研究纳入了Troms?第四次临床研究中的24799名研究对象(平均年龄为45.5±14.2岁,女性占52.9%),经过平均15.7±5.5年时间的随访,有811名(6.2%)女性和918名(7.9%)男性发展为房颤,在男性中,低的BMI可以降低房颤的发生风险,而高BMI会增加房颤的风险(HR:4.42 ;95% Cl:[3.00-6.53]),女性中也有相似的结果,与男性无明显差异。研究结果显示,体重指数与房颤的发生风险呈正相关,BMI越高,房颤发生风险越大,这种相关性无性别差异。原始出处:Jocasta B et al.Sex Differences in the Impact of Body Mass Index on the Risk of Future Atrial Fibrillation: Insights From the Longitudinal Population‐Based Tromsø Study.JAHA.2018 Apr.本文系梅斯医学(MedSci)原

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994514, encodeId=0883199451446, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 15:34:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267800, encodeId=e6a6126e80016, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 22 01:34:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307738, encodeId=5cd730e73885, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Apr 21 00:25:43 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307583, encodeId=3a4830e583fe, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Fri Apr 20 11:25:56 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994514, encodeId=0883199451446, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 15:34:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267800, encodeId=e6a6126e80016, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 22 01:34:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307738, encodeId=5cd730e73885, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Apr 21 00:25:43 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307583, encodeId=3a4830e583fe, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Fri Apr 20 11:25:56 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-22 zhaohui6731
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994514, encodeId=0883199451446, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 15:34:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267800, encodeId=e6a6126e80016, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 22 01:34:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307738, encodeId=5cd730e73885, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Apr 21 00:25:43 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307583, encodeId=3a4830e583fe, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Fri Apr 20 11:25:56 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-21 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1994514, encodeId=0883199451446, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 15:34:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267800, encodeId=e6a6126e80016, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 22 01:34:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307738, encodeId=5cd730e73885, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Apr 21 00:25:43 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307583, encodeId=3a4830e583fe, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Fri Apr 20 11:25:56 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-20 戒馋,懒,贪

    谢谢分享学习了

    0

相关资讯

Eur Heart J:西地那非不能改善心脏瓣膜置换术后持续性肺动脉高压患者预后

本研究的目的旨在探究西地那非是否能改善心脏瓣膜疾病(VHD)矫正后持续性肺动脉高压患者的预后。本次多中心随机双盲对照临床研究纳入了200名1年前接受过心脏瓣膜置换术且平均肺动脉压力≥30mmHg的成年患者,其中104名患者接受了西地那非治疗,96名患者接受了安慰剂治疗,时间长达6个月,主要终点事件是死亡、心衰入院、功能分级改变和患者自我评估的临床综合评分。分析结果显示,西地那非组仅27名患者的临床

JAHA:焦虑可增加房颤患者的卒中发生风险!

焦虑和抑郁会加重许多心血管疾病的预后结局,然而其是否会影响房颤患者的预后尚属未知。本研究的目的旨在评估房颤患者中焦虑和/或抑郁是否与卒中和出血事件的发生相关。本研究纳入了2004年至2007年WAVE数据库中接受华法林治疗的房颤患者,通过电子病历记录对患者进行焦虑和抑郁的诊断。最终共纳入了25570名房颤患者,其中490名患者出现了卒中或脑出血(1.52次/100人年),多变量分析后发现,焦虑会增

JAHA:青少年的心血管健康状态堪忧

理想心血管健康状态(ICH)是一个较新的概念,本研究的目的旨在评估不同程度肥胖青少年的ICH比例,尤其是严重肥胖青少年中ICH的比例。本横断面研究对300名儿童和青少年进行了ICH的详细评估调查,并根据对象的肥胖程度分为正常体重组、超重组和严重肥胖组。ICH评估体系由7个不同的指标组成,并分为差、中等和良好三个等级。在300个研究对象(平均年龄12.8岁,女性占48%)中,113名为正常体重组,8

盘点:JACC4月第3期研究一览

1. 经导管主动脉瓣置换术数量呈逐年上升趋势DOI: 10.1016/j.jacc.2018.01.079经导管主动脉瓣置换术(TAVR)已经逐渐成为替代外科主动脉瓣置换术(SAVR)的一个选择。本研究纳入了2007年至2015年法国住院数据库中接受AVR治疗的患者,最终共纳入了131251名研究对象:其中SAVR有109317名 (83%),TAVR有21934名 (17%)。AVR数量随时间呈

JACC:他汀类药物治疗中的“性别歧视”

目前,相比于女性,医生会普遍倾向于男性更应该接受他汀类药物治疗作为心梗的二级预防。本研究的目的旨在评估心梗后接受高强度他汀类药物治疗患者中的性别差异。本研究纳入了MarketScan数据库中16898名(女性占26%)有商业医疗保险的年龄小于65岁的成年人,以及71358名(女性占49%)2014年至2015年年龄≥66岁的心梗出院后接受有他汀类处方药物治疗的患者。分析结果显示,在2014年至20

JACC:阿司匹林与NSAIDs共同服用的安全性研究

目前,关于非甾体抗炎药(NSAID)与阿司匹林共同服用的安全性如何尚不清楚。本研究的目的旨在评估NSAIDs与低剂量阿司匹林共同服用的安全性。本研究纳入了PRECISION临床试验中的23953名被随机分配接受塞来昔布、布洛芬或萘普生治疗的骨关节炎或类风湿性关节炎的患者,主要终点事件包括复合的主要不良心血管事件、非心血管死亡、胃肠或肾不良事件及其复合事件。分析结果显示,在不与阿司匹林共同服用的患者